The global proteomics market was valued at over USD 11.8 billion in 2015. The growing incidence of target diseases such as cancer, diabetes, and cardiovascular is expected to be the major factor for market growth. Customized therapies and medicines such as protein sequencing are under research for such diseases. The sudden climatic changes, unhealthy lifestyle, and low awareness about infectious diseases in low-income countries foster the demand for better diagnosis of fatal diseases.
The goal of studying proteomics in the 21st century is to be able to detect diseases at early stages. An inordinate progress is being made in the past few years, as proteomics proves to be a very powerful tool for providing information pertaining to a broad range of diseases. Recent advancement in this field includes multiple reactions monitoring, which quantifies the proteins in the cerebrospinal fluid for the detection of later stages of multiple sclerosis.
U.S. Proteomics Market By Product, USD Million, 2013 - 2024
Furthermore, regulations and government policies support the research and development (R&D) in proteomics. The Center for Biologics Evaluation and Research regulates the approval of all the biological products related to proteomics by ensuring their safety and efficacy. The FDA is also engaged in studying the use of analytical proteomic tools for characterizing biological products and for validation of biomarkers.
Growing prevalence of target diseases is driving the market. Cardiovascular diseases are the leading cause of death globally. For instance, according to WHO (2021), target diseases kill 41 million patients each year. According to a study by, Global Burden of Disease in 2021, it was estimated that 24.8% of deaths happening in India are due to cardiovascular diseases. This creates a market opportunity to supply proteomics-based products, in these regions and gain market share.
Technological advancements in the field of healthcare, improved public health policies, and improvements in living conditions have increased the life span of humans. The increase in the geriatric population is anticipated to be a major factor in the growth of the market. The incidence of this infection has increased substantially, particularly in geriatric patients, owing to the exposure to healthcare settings such as hospitals and long-term care facilities. Increasing incidence coupled with advanced proteomics medicines is expected to propel the market growth over the forecast period
In the proteomics market, the increased usage of Nano-proteomics provides a lucrative prospect. Nanotechnology aids in the study of post-translational modifications (PTM), a wide spectrum of molecules, and the intricacies of biology in the subject. Nano proteomics has exploded the complexity furthermore, increased proteome usage in emerging economies such as China, India, and others would expand the proteomics industry.
The increasing geriatric population is driving the market. According to WHO, the proportion of the world’s geriatric population from 2015 to 2050 will double from 12% to 22%. By 2030, 1 out of 6 people will be in the geriatric population, and the geriatric population will increase from 1 billion in 2020 to 1.4 billion by 2050. According to the UN, the geriatric population is anticipated to increase to 2.1 billion by 2050 from 962 million in 2018. With increasing demand to opt for personalized medicine from geriatric patients becoming a market driver for proteomics market.
The regulatory framework for the proteomics market is ambiguous, it is one of the major restraints for the market growth. There is a big risk of privacy issues around clinical proteomics data. Human genome is considered an extremely advanced identifier of people as large numbers of their aggregates can be ultimately anticipated from their genomes by utilizing keen computer algorithms. To control this the regulatory framework is ambiguous, due to complex and hard-to-enter market it becomes a challenge for the market to grow.
To find the chemicals that either stimulate or disable target proteins, companies rely on publicly available structural data and trial-and-error procedures. Protein structure is achieved by the use of high-throughput techniques and machinery. Gene cloning, protein expression, purification, and crystallization of proteins are all done using X-ray crystallography, which is one of the most extensively used procedures in proteomics. All of these procedures necessitate a substantial number of laboratory hours, raising the cost of testing per sample. Because of the high cost of instruments and reagents, developing nations find it difficult to enter the field of proteomics.
The regents segment was estimated to be the largest and the fastest-growing segment in 2015, owing to factors such as widespread research in academic institutes coupled with high frequency of usage of reagent, kits, chemicals, and strips for the analysis of various biological samples.
The introduction of technologically advanced instruments, such as 2-D electrophoresis protein analyzers, is projected to exhibit significant growth over the forecast period. Instruments such as biochip analyzers and electrophoresis instruments are majorly used for the quantification of proteins.
The large-scale analysis of proteins through techniques such as x-ray crystallography, protein fractionation systems, microarray, and surface plasma resonance provides the view of molecular and cellular functions that give access to overall information of the complex processes in the living systems. The increasing importance of such studies for targeted diagnosis and treatment leads to rise in demand for the proteomics market over the forecast period.
The microarray segment was identified as the largest segment with revenue of over USD 5.6 billion in 2015. The ability of microarrays to produce more information from small samples is the major factor contributing toward its large market share. Microarray gives the advantage of label-free detection, direct and absolute quantification, and full imprint of proteins.
The introduction of new technology such as use of mass spectroscopy to analyze biological samples is expected to propel the spectroscopy industry growth over the forecast period.
Proteomics is used for various purposes such as protein expression profiling, proteome mining, structural and functional proteomics, and to study posttranslational modifications. Clinical diagnosis is also expected to foresee a lucrative growth due to its wide range of applications that include disease biomarker discovery, host-pathogen interaction, personalized medicines, the study of disease pathogenesis, and identification of drug target. Moreover, the introduction of technologically advanced instruments, increasing awareness on newer diagnostic techniques, and the increasing usage of personalized medicines are the factors responsible for its high growth.
North America dominated the proteomics market and accounted for the largest revenue share of 46% in 2021. The region is anticipated to show growth over the forecast period. This growth can be attributed to increasing investments in the development of structure-based drug design, increasing focus on developing personalized therapeutics, growing research in the field of proteomics, and rising demand for high-quality research tools for data reproducibility, substantial funding from the government for research. The presence of key market players in this region is also anticipated to support the growth of the market.
The U.S. proteomics market is driven by a wide range of proteomics offered, presence of key market players, government initiatives, consumer awareness about the emerging technologies, increase in popularity of personalized medicines among patients, advancements in research and development, and collaborations among key market players in the region. For instance, in September 2021, SomaLogic and BOULDER entered into a collaboration to investigate how large-scale research on proteins and their functions in the body can be used in clinical care. Such advancements and collaborations are driving the U.S. proteomics market.
An increase in proteomics-based outsourcing, government and private funding for research and development for proteomics studies, favorable government policies, growing prevalence of target diseases with a growing geriatric population, and rising proteomics adoption are reasons for growth of the proteomics market in India. For instance, in November 2021, Department of Biotechnology, Government of India, granted funding of INR 60 million to University of Hyderabad, for study of proteomics in tomatoes. Such government initiatives to support the proteomics study are driving the market in India.
Some key players include Roche Diagnostics, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., and GE Healthcare. These companies are involved extensively in the R&D initiatives for the development of various proteomics-related diagnostic kits and reagents. Collaboration with kit manufacturers for the development of instrument-compatible kits is a major strategic initiative undertaken by the industry players to sustain their industry position. For instance, Sygnis, a Germany-based company had acquired Expedeon Ltd. to expand its product portfolio of NGS reagents.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.